Suppr超能文献

贲门失弛缓症治疗的药物疗法:现状、挑战与未来方向

Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

作者信息

Nassri Ammar, Ramzan Zeeshan

机构信息

Ammar Nassri, Department of Internal Medicine, University of Texas at Austin Dell Medical School, Austin, TX 78701, United States.

出版信息

World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):145-55. doi: 10.4292/wjgpt.v6.i4.145.

Abstract

This article reviews currently available pharmacological options available for the treatment of achalasia, with a special focus on the role of botulinum toxin (BT) injection due to its superior therapeutic effect and side effect profile. The discussion on BT includes the role of different BT serotypes, better pharmacological formulations, improved BT injection techniques, the use of sprouting inhibitors, designer recombinant BT formulations and alternative substances used in endoscopic injections. The large body of ongoing research into achalasia and BT may provide a stronger role for BT injection as a form of minimally invasive, cost effective and efficacious form of therapy for patients with achalasia. The article also explores current issues and future research avenues that may prove beneficial in improving the efficacy of pharmacological treatment approaches in patients with achalasia.

摘要

本文综述了目前可用于治疗贲门失弛缓症的药物选择,特别关注肉毒杆菌毒素(BT)注射的作用,因为其具有卓越的治疗效果和副作用特征。关于BT的讨论包括不同BT血清型的作用、更好的药物制剂、改进的BT注射技术、发芽抑制剂的使用、定制重组BT制剂以及内镜注射中使用的替代物质。目前对贲门失弛缓症和BT的大量研究可能会使BT注射作为一种微创、经济有效且高效的治疗方式在贲门失弛缓症患者中发挥更重要的作用。本文还探讨了当前的问题以及未来的研究途径,这些可能有助于提高贲门失弛缓症患者药物治疗方法的疗效。

相似文献

1
Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):145-55. doi: 10.4292/wjgpt.v6.i4.145.
2
A modified method of botulinum toxin injection in patients with achalasia: a pilot trial.
Endoscopy. 2003 Oct;35(10):841-4. doi: 10.1055/s-2003-42621.
3
Review article: the management of achalasia - a comparison of different treatment modalities.
Aliment Pharmacol Ther. 2006 Sep 15;24(6):909-18. doi: 10.1111/j.1365-2036.2006.03079.x.
4
The role of Botulinum toxin injection in the management of achalasia.
Curr Opin Gastroenterol. 2013 Jul;29(4):468-73. doi: 10.1097/MOG.0b013e328362292a.
5
Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study.
Dis Esophagus. 2003;16(3):204-9. doi: 10.1046/j.1442-2050.2003.00329.x.
6
Achalasia: what is the best treatment?
Ann Afr Med. 2008 Sep;7(3):141-8. doi: 10.4103/1596-3519.55662.
8
Safety and efficacy of botulinum toxin injection therapy for esophageal achalasia in Japan.
J Clin Biochem Nutr. 2015 Nov;57(3):239-43. doi: 10.3164/jcbn.15-47. Epub 2015 Oct 17.

引用本文的文献

2
Evolving therapeutic approaches in achalasia: a comprehensive review of peroral endoscopic myotomy (POEM) vs. Heller's myotomy.
Ann Med Surg (Lond). 2025 Apr 10;87(5):2855-2867. doi: 10.1097/MS9.0000000000003271. eCollection 2025 May.
3
Surgical management of achalasia.
Abdom Radiol (NY). 2025 Jun;50(6):2351-2357. doi: 10.1007/s00261-024-04664-3. Epub 2024 Nov 25.
5
Endoscopic ultrasound: a powerful tool to modify treatment algorithms in opioid-induced achalasia.
Surg Endosc. 2021 Aug;35(8):4585-4594. doi: 10.1007/s00464-020-07882-0. Epub 2020 Aug 26.
6
Esophagogastric Junction Outflow Obstruction: Current Approach to Diagnosis and Management.
Curr Gastroenterol Rep. 2020 Feb 5;22(2):9. doi: 10.1007/s11894-020-0743-0.
7
Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.
Dig Dis Sci. 2020 Jan;65(1):38-65. doi: 10.1007/s10620-019-05784-3. Epub 2019 Aug 27.
8
Bridging therapy for achalasia in a second trimester pregnant patient.
J Family Med Prim Care. 2019 Jan;8(1):289-297. doi: 10.4103/jfmpc.jfmpc_389_18.
9
An Overview of Achalasia and Its Subtypes.
Gastroenterol Hepatol (N Y). 2017 Jul;13(7):411-421.

本文引用的文献

1
Achalasia: a systematic review.
JAMA. 2015 May 12;313(18):1841-52. doi: 10.1001/jama.2015.2996.
3
Peroral esophageal myotomy versus laparoscopic Heller's myotomy for achalasia: a meta-analysis.
J Laparoendosc Adv Surg Tech A. 2015 Feb;25(2):123-9. doi: 10.1089/lap.2014.0454.
4
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.
Drugs R D. 2015 Mar;15(1):1-9. doi: 10.1007/s40268-014-0077-1.
5
Acrylamide inhibits nerve sprouting induced by botulinum toxin type A.
Neural Regen Res. 2014 Aug 15;9(16):1525-31. doi: 10.4103/1673-5374.139479.
6
8
Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells.
PLoS One. 2014 Feb 27;9(2):e90252. doi: 10.1371/journal.pone.0090252. eCollection 2014.
9
Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
Toxicon. 2014 May;82:52-60. doi: 10.1016/j.toxicon.2014.02.004. Epub 2014 Feb 21.
10
Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant.
Hum Immunol. 2014 Apr;75(4):364-9. doi: 10.1016/j.humimm.2014.01.004. Epub 2014 Jan 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验